Major Depressive Disorder Pipeline Insight Report 2021: Comprehensive Insights About 200+ Companies and 200+ Pipeline Drugs – ResearchAndMarkets.com

Major Depressive Disorder Pipeline Insight Report 2021: Comprehensive Insights About 200+ Companies and 200+ Pipeline Drugs – ResearchAndMarkets.com




Major Depressive Disorder Pipeline Insight Report 2021: Comprehensive Insights About 200+ Companies and 200+ Pipeline Drugs – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Major Depressive Disorder – Pipeline Insight, 2021” drug pipelines has been added to ResearchAndMarkets.com’s offering.

This “Major Depressive Disorder – Pipeline Insight, 2021,” report provides comprehensive insights about 200+ companies and 200+ pipeline drugs in Major Depressive Disorder pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Major Depressive Disorder R&D. The therapies under development are focused on novel approaches to treat/improve Major Depressive Disorder.

Major Depressive Disorder Emerging Drugs Chapters

This segment of the Major Depressive Disorder report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Major Depressive Disorder Emerging Drugs

SAGE-217: Sage Therapeutics

SAGE-217 is an investigational, oral, novel medicine in development for depression. SAGE-217 is an investigational oral neuroactive steroid (NAS) GABAA receptor positive allosteric modulator (PAM). The GABA system is the major inhibitory signaling pathway of the brain and central nervous system (CNS), and contributes significantly to regulating CNS function. The drug is being studied in phase III stage of development for the treatment of Major depressive disorder.

REL-1017: Relmada Therapeutics, Inc

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for REL-1017 as an adjunctive treatment of MDD. REL-1017, an NCE and novel NMDAR channel blocker with a preference for hyperactive channels associated with MDD, has entered its Phase 3 registration program as an adjunctive treatment for MDD.

Seltorexant: Minerva Sciences

Seltorexant is an innovative selective orexin 2 receptor antagonist under development for the treatment of insomnia and related mood disorders. Insomnia is the repeated difficulty with sleep initiation, maintenance or quality that occurs despite adequate time and opportunity for sleep, resulting in daytime impairment. The clinical trials are being carried out for the treatment of major depressive disorder in phase III stage of development.

SP-624: Sirtsei Pharmaceuticals, Inc.

SP-624 is being studied in phase II stage of development for the treatment of major depressive disorder in comparison with placebo by Sirtsei Pharmaceuticals, Inc.

SPL026: Small Pharma

SPL026 is N, N-DIMETHYLTRYPTAMINE (DMT) AND DEUTERIUM-ENRICHED TRYPTAMINES therapy For Psychedelic -Assisted Psychotherapy as a Rapid onset, sustained treatment for mental health disorders. Phase I/IIa trial of DMT-assisted therapy in both healthy volunteers and patients in London is being carried out by Small Pharma.

PDC-1421: BioLite Inc

PDC-1421 (BLI-1005) is a Norepinephrine plasma membrane transport protein inhibitor being developed by BioLite Inc, for the treatment of major depressive disorder. The drug is currently in phase II stage of development.

Major Players in Major Depressive Disorder

There are approx. 200+ key companies which are developing the therapies for Major Depressive Disorder. The companies which have their Major Depressive Disorder drug candidates in the most advanced stage, i.e. phase III include SAGE Therapeutics.

Phases

This report covers around 200+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

Route of Administration

Major Depressive Disorder pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Subcutaneous
  • Intravenous
  • Intramuscular

Molecule Type

Products have been categorized under various Molecule types such as

  • Bispecific Antibody
  • Peptides
  • Small molecule
  • Gene therapy
  • Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Major Depressive Disorder: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Major Depressive Disorder therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Major Depressive Disorder drugs.

Major Depressive Disorder Report Insights

  • Major Depressive Disorder Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Major Depressive Disorder Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions Answered

  • How many companies are developing Major Depressive Disorder drugs?
  • How many Major Depressive Disorder drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Major Depressive Disorder?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Major Depressive Disorder therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Major Depressive Disorder and their status?
  • What are the key designations that have been granted to the emerging drugs?

Companies Mentioned

  • Acadia Pharmaceuticals
  • Alkermes, Inc.
  • Allergan
  • Axsome Therapeutics, Inc.
  • BioLite Inc
  • BlackThorn Therapeutics
  • Boehringer Ingelheim
  • Chase Therapeutics Corporation
  • Clexio Biosciences Ltd.
  • Gate Neurosciences, Inc
  • Janssen Research & Development, LLC
  • Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
  • Luye Pharma
  • Minerva biosciences
  • Naurexx, Inc
  • NeuroRx Inc
  • Novartis Pharmaceuticals
  • Otsuka Pharmaceuticals
  • Relmada therapeutics, Inc
  • Sage Therapeutics
  • Seelos Therapeutics, Inc.
  • Shenox Pharmaceuticals, LLC
  • Sirtsei Pharmaceuticals, Inc.
  • Small Pharma Ltd
  • Suven Life Sciences Limited

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/bz3zg7

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900